So why do so many preclinical publications contain research that can’t be reproduced?

The blame may be attributable to the lack of double-blind experiments which, while required in clinical trials, are rarely enforced in preclinical settings. In the absence of double-blind conditions, there is a risk that researchers—driven by a desire to get high impact publications to support their tenure and grant funding aspirations—selectively publish positive results. Further, with an increasing number of researchers around the globe competing for grant funding and tenure positions, there may be decreasing incentives for collaboration in reproducing preclinical results. #ScienceInCrisis
Shared publicly